Chemomab Therapeutics (CMMB) Stock Analysis

What Chemomab Therapeutics does

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

Key metrics

ETFs linked to CMMB

Broad-market and Healthcare sector ETFs an investor holding Chemomab Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CMMB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Chemomab Therapeutics?

Chemomab Therapeutics trades under the ticker CMMB on NASDAQ.

Which exchange is CMMB listed on?

CMMB is listed on NASDAQ.

What sector does Chemomab Therapeutics operate in?

Chemomab Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CMMB in a portfolio?

PortView shows CMMB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.